Patents by Inventor Megan Levings

Megan Levings has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
    Publication number: 20240067732
    Abstract: The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.
    Type: Application
    Filed: September 27, 2023
    Publication date: February 29, 2024
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, SANGAMO THERAPEUTICS FRANCE
    Inventors: Li Zhou, Tobias Abel, François Meyer, Megan Levings, Nicolas Dawson, Caroline Lamarche
  • Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof
    Patent number: 11814432
    Abstract: The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: November 14, 2023
    Assignees: The University of British Columbia, Sangamo Therapeutics France
    Inventors: Li Zhou, Tobias Abel, François Meyer, Megan Levings, Nicolas Dawson, Caroline Lamarche
  • ANTI-HLA-A2 ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20200283529
    Abstract: Provided are humanized anti-HLA-A2 antibodies. In certain aspects, the humanized anti-HLA-A2 antibodies are capable of constituting an antigen binding domain of a chimeric antigen receptor (CAR), where the CAR is capable of being expressed in a human cell such that the CAR specifically binds to HLA-A2. Also provided are CARs that include the humanized anti-HLA-A2 antibodies. Modified cells including the antibodies and CARs, as well as methods of using such modified cells are also provided.
    Type: Application
    Filed: September 19, 2018
    Publication date: September 10, 2020
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, CDRD VENTURES INC.
    Inventors: Megan LEVINGS, Paul ORBAN, Nicholas DAWSON, Caroline LAMARCHE, Jan Peter BERGQVIST
  • NOVEL ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
    Publication number: 20200283530
    Abstract: The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.
    Type: Application
    Filed: September 20, 2018
    Publication date: September 10, 2020
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, SANGAMO THERAPEUTICS FRANCE
    Inventors: Li ZHOU, Tobias ABEL, François MEYER, Megan LEVINGS, Nicolas DAWSON, Caroline LAMARCHE
  • EX-VIVO ISOLATED CD25+CD4+ T CELLS WITH IMMUNOSUPPRESSIVE ACTIVITY AND USES THEREOF
    Publication number: 20090010950
    Abstract: Ex-vivo isolated human CD25+CD4+ T regulatory cells, CD25+CD4+ Tr cell clones derived therefrom, a method of isolating clones and the use of ex-vivo isolated human CD25+CD4+ Tr cells or cell-clones as immunomodulators, immunosuppressive agents or for the identification of molecules that modulate the immune response.
    Type: Application
    Filed: September 8, 2008
    Publication date: January 8, 2009
    Applicant: FONDAZIONE TELETHON
    Inventors: Maria Grazia RONCAROLO, Megan Levings
  • Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof
    Publication number: 20040173778
    Abstract: Ex-vivo isolated human CD25+CD4+ T regulatory cells, CD25+CD4+ Tr cell clones derived therefrom, a method of isolating clones and the use of ex-vivo isolated human CD25+CD4+ Tr cells or cell-clones as immunomodulators, immunosuppressive agents or for the identification of molecules that modulate the immune response.
    Type: Application
    Filed: May 7, 2004
    Publication date: September 9, 2004
    Inventors: Maria Grazia Roncarolo, Megan Levings